Fylkesvise forskjeller i overlevelse av brystkreft

Tidsskrift for den Norske Laegeforening

Volumn 129, Issue 24, 2009, Pages 2595-2600

  Kalager, Mette ^a   Kåresen, Rolf ^b   Wist, Erik ^b  

^a Kreftregisteret   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; MAMMOGRAPHY; MASS SCREENING; MORTALITY; NORWAY; REGISTER; SURVIVAL; SURVIVAL RATE;

BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; MAMMOGRAPHY; MASS SCREENING; NORWAY; QUALITY ASSURANCE, HEALTH CARE; REGISTRIES; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 74049084521     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.0024     Document Type: Article

References (36)

1. Kreftregisteret. Cancer in Norway 2006. www.kreftregisteret.no (15.4.2009).
2. Kreftregisteret. Kreftstatistikk. www.kreftregisteret.no/no/Registrene/ Kreftstatistikk/ (15.4.2009).
3. Statistisk sentralbyrå. Statistikkbanken. Helse, sosiale forhold og kriminalitet. http://statbank.ssb.no/statistikkbanken/Default_FR.asp?Productid=03.01&PXSid=0&nvl=true&P Language=0&tilside=selecttable/MenuSelP. asp&SubjectCode=03 (13.9.2008).
4. Zahl PH, Strand BH, Mæhlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: Prospective cohort study. BMJ 2004; 328: 921-4.
5. Nyström L, Andersson I, Bjurstam N et al. Long term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909-19.
6. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-717.
7. Stockton D, Davies T, Day N et al. Retrospective study for reasons for improved survival in patients with breast cancer in East Anglia: earlier diagnosis or better treatment? BMJ 1997; 314: 472-5.
8. Giuliano AE, Dale PS, Turner RR et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222: 394-9.
9. Norsk Bryst Cancer Gruppe. www.nbcg.no/nbcg.blaaboka.html (27.4.2009).
10. St.prp. nr 1 (2005-2006). Strategisk arbeid på kreftområdet. www.regjeringen.no/nb/dep/hod/dok/regpubl/stprp/20052006/Stprp-nr-1-2005-2006-/7.html?id=211309 (27.4.2009).
11. Dalgard OS, Rognerud M, Strand BH. Psykisk helse i Helse og levekårsundersøkelsen i 1998. II. Geografiske forskjeller. Norsk Epidemiologi 2002; 12: 249-56. www.ub.ntnu.no/journals/norepid/ 2002-3/2002(3)Dalgard.pdf (15.4.2009).
12. Raabe NK, Fossa SD, Karesen R. Primær invasiv cancer mammae i Oslo 1980-89. Tidsskr Nor Lægeforen 1997; 117: 3778-83.
13. Raabe NK, Kaaresen R, Fosså SD. Analysis of adjuvant treatment in postmenopausal patients with stage II invasive breast carsinoma. A pattern of care study and quality assurance of 431 consecutive patients in Oslo. Acta Oncol 1997; 36: 255-60.
14. Kravdal Ø. Does place matter for cancer survival in Norway? A multilevel analysis of the importance of hospital affiliation and municipality socio-economic resources. Health Place 2006; 12: 527-37.
15. Eaker S, Dickman PW, Hellström V et al. Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev 2005; 14: 2914-8.
16. Sobin LH, Wittekin C, red. TNM classification of malignant tumors. 6. utg. Hoboken, NJ: John Wiley & Sons, 2002.
17. Kalager M, Haldorsen T, Bretthauer M et al. Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: A population-based cohort study. Breast Cancer Res 2009; 11: R44.
18. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604-8.
19. van Rijk MC, Peterse JL, Nieweg OE et al. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer 2006; 107: 467-71.
20. Mullee MA, De Stavola B, Romanengo M et al. Geographical variation in breast cancer survival rates for women diagnosed in England between 1992 and 1994. Br J Cancer 2004; 90: 2153-6.
21. Birkmeyer JD, Stukel TA, Siewers AE et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349: 2117-27.
22. Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346: 1138-44.
23. Sainsbury R, Haward B, Rider L et al. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995; 345: 1265-70.
24. Skinner KA, Helsper JT, Deapen D et al. Breast cancer: do specialists make a difference? Ann Surg Oncol 2003; 10: 606-15.
25. Gilligan MA, Neuner J, Zhang X et al. Relationship between number of breast cancer operations performed and 5-year survival after treatment for early-stage breast cancer. Am J Public Health 2007; 97: 539-44.
26. Gillis C, Hole D. Survival outcome of care by specialist surgeons in breast cancer. A study of 3786 patients in the west of Scotland. BMJ 1996; 312: 145-8.
27. Kingsmore D, Hole D, Gillis C. Why does specialist treatment of breast cancer improve survival? The role of surgical management. Br J Cancer 2004; 90: 1920-5.
28. Pass Ha, Klimberg SV, Copeland EM 3rd. Are breast-focused surgeons more competent? Ann Surg Oncol 2008; 15: 953-5.
29. Nattinger AB, Laud PW, Sparapani RA et al. Exploring the surgeon volume-outcome relationship among women with breast cancer. Arch Intern Med 2007; 167: 1958-63.
30. Welch HG, Black WC. Are deaths within 1 month of cancer-directed surgery attributed to cancer? J Natl Cancer Inst 2002; 94: 1066-70.
31. Tjemsland L, Søreide JA. Når kreftsykdommer kommer i tillegg...Tidsskr Nor Lægeforen 2001; 121: 1046-51.
32. Robsahm TE, Tretli S. Weak associations between sociodemographic factors and breast cancer: Possible effects of early detection. Eur J Cancer Prev 2005; 14: 7-12.
33. Folkehelseinstituttet. Reseptregisteret. www.reseptregisteret.no (13.9.2008).
34. Statistisk sentralbyrå. Samlet fruktbarhetstall. www.ssb.no/emner/02/02/10/fodte/tab-2009-04-02-05.html (23.4.2009).
35. Møller P, Heimdal K, Apold J et al. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 2001; 37: 2428-34.
36. Møller P, Evans DG, Reis M et al. Surveillance for familial breast cancer: Differences in outcome to BRCA mutation status. Int J Cancer 2007; 121: 1017-20.